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ABSTRACT
Objective: Identify the influence of ovarian hormone deprivation in expression genes on the lower urinary tract of rats.
Materials and Methods: This study deals with gene screening on lower urinary tract of rats. Fifty isogenic rats divided in
two groups of twenty-five animals have their lower urinary tract surgically removed: group I, ovariectomized rats 30 days
prior to surgery; group II, non-ovariectomized rats. Total RNA was isolated from bladder and urethra, and differential
expression of genes was analyzed quantitative, qualitative and comparatively by array technology and RT-PCR.
Results: A total of 76 candidate genes were identified as differentially expressed between the groups, 26 being lower
expressed in group II, and 50 in group I. Among them, differential expression validation was confirmed by RT-PCR for three
lower expressed genes in group I: Vascular Endothelial Growth Factor (VEGF), Beta-2 Microglobulin (B2M) and Cytochrome
c Oxidase subunit I (COX I).
Conclusion: Ovarian hormone deprivation influences the expression genes on lower urinary tract. We demonstrated that a
30-day period of castration down regulate the expression of VEGF, B2M and COX I in adult rats which are involved in
activities of angiogenesis, immune responses and cellular metabolism respectively.
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INTRODUCTION
The climacterium, a period of decline in ova-
rian activity, is characterized by a variety of symp-
toms, in particular urogenital ones (1). Studies dem-
onstrated a high incidence of urogenital symptoms in
the climacterium and postmenopausal period, associ-
ating them to estrogen deficiency as the etiologic fac-
tor. Iosif & Bekassy (1), on studying 902 patients,
observed approximately 29% urinary incontinence,
27% urge incontinence, 13% repeated infections of
the urinary tract and 48% other symptoms due to uro-
genital atrophy, such as dysuria, dyspareunia, nocturia,
micturition urgency.
It was believed sexual hormones deprivation
would cause, among other modifications, urinary mu-
cosa and muscle layer atrophy, increase in collagen/
smooth muscle ratio in the urinary tract, decrease in
pelvic vascularization, decrease in the protecting
glycosaminoglycan layer in the vesical wall, modifi-
cations of the vaginal flora and pH, alterations in the
cellular and humoral immunologic responses (2-10).
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545
Gene  Expression  in  The  Lower  Urinary  Tract
These findings had supported estrogen deprivation as
the origin of urinary disorders on postmenopausal
women. In fact, for many years, estrogen prepara-
tions have been used to treat urinary symptoms and
they are no longer a treatment option for urinary in-
continence (11,12).
Presently, the identification of some medicines
starts by recognizing the genes that might be involved
in pathological processes that, therefore, could be
qualified as targets for future pharmacological inter-
ventions (13,14). In order to understand the way genes
regulate cell function, the best procedure is by moni-
toring the set of gene activities in the cells (15).
Microarray technology appeared in the last decade
and constitutes an instrument able to quantitatively,
qualitatively and simultaneously monitor hundreds or
even thousands of genes (16,17). The use of arrays
allows the global statistical analysis of the behavior of
the different genes in certain evaluated situations and
permits a dynamic analysis of the target tissue, since
it compares expressions of the several genes among
themselves (18,19).
We studied the influence of ovarian hormones
deprivation on gene expression in the lower urinary
tract, attempting to correlate biomolecular findings with
mechanisms involved in urogynecologic diseases.
MATERIALS AND METHODS
Specimens - Rattus novergicus albinus (Ro-
dentia Mammalia - Wistar EPM-1) from the animal
house of the Federal University of São Paulo/EPM
were kept in environmentally controlled, clean-air
rooms with a 12-h light/dark cycle. They were fed
Labina-Purina-SP-BR pellets and tap water ad libi-
tum. Fifty virgin rats, 2-3 months old, were divided
into 2 groups of twenty-five animals: Group I, rats
that had their bladder and urethra removed 30 days
after ovariectomy; Group II, non-ovariectomized rats
that had their lower urinary tract removed 30 days
afterwards. At the above indicated time, the corre-
sponding animals were anesthetized; lower urinary
tracts were rapidly frozen in liquid nitrogen for RNA
extraction. This study received full Institutional Re-
view Board approval.
RNA Extraction and Reverse Transcription -
Total RNA was extracted from samples using TRIZOL
(InVitrogen, São Paulo) according to the manufacture’s
instructions. The total RNA quality was checked by
formaldehyde/agarose gel electrophoresis. Prior to
reverse transcriptions, two pools of RNA were ob-
tained by mixing 2 µg of total RNA from each indi-
vidual case in two tubes representing Group I and II.
In order to obtain radiolabeled cDNA probes, the two
RNA pools, containing 50 µg RNA each, were re-
verse transcribed in the presence of oligodT primers
and α-[33P] dATP (2000 Ci/mmoL) by using kit Su-
perscript II (InVitrogen) following the manufacture’s
instructions. Probes were purified by Probe Quant G50
microcolumns (Amersham Pharmacia Biotech).
cDNA Arrays and Hybridization Conditions -
To analyze different gene expressions between group
I and II, two Atlas rat cDNA expression array mem-
branes (Clontech, Palo Alto, CA, USA) containing
1176 genes were used (two times). Hybridization took
place at 42oC in an overnight reaction containing 20X
standard saline citrate (SSC), 50X Denhardt’s solu-
tion, 50% formamide, 10x sodium dodecyl sulphate
(SDS) and 100 µg/mL salmon-sperm DNA. The fil-
ters were washed at 50oC in 1x SSC/0, 1% SDS for
15 minutes. Images were obtained by scanning the
membrane in a storage phosphor system (Cyclone
- Packard BioScience Company, Meriden, CT, USA).
DNA targets on the arrays were located using grid
overlays and spot intensities were subsequently mea-
sured (Diracom Bioinformática - São Paulo/Brazil).
Statistical Usage - Signs generated by hybrid-
ization of radioactive probes were processed and nor-
malized using the digital software ArrayLab (Diracom
Bioinformática - São Paulo, Brazil), by means of a
superposing digital grid instrument on the cDNA spots
marked on the nylon membranes. Thus, the expres-
sion of each gene was quantified by the calculation of
the radiation volume (three-dimensional) emitted by
the previously known spots of the membranes, con-
sequently obtaining the numeric value corresponding
to the images, on a logarithmic basis. We obtained the
difference (DIF) of the expression of the same gene
in the two groups (I and II) by the formula: DIF =
log2(II-I). Values of DIF > 1 or < 1 were considered
differentially expressed, that is, twice the difference
in expression between the genes. The housekeeping
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genes of the membranes, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), cytoplasmic beta actin
(ACTB) and ubiquitin C had values of expression dif-
ference between the groups within the interval -1 <
DIF < 1.
RT-PCR - Validation of array data by semi-
quantitative RT-PCR was performed by pooling equal
amounts of total RNA from each group; pools were
then submitted to reverse transcription by using Su-
perscript II RNAse H reverse transcriptase
(InVitrogen) in a final volume of 20 µL according to
the manufacture’s instructions. Primers were designed
by Prime3 program-http://www-genome.wi.mit.edu/
cgi-bin/primer/primer3.cgi/primer3_www.cgi). Cyto-
plasmic beta actin (ACTB) gene was used to normal-
ize the reactions. Two microliters of the reverse tran-
scribed cDNA was amplified in a final volume of 100
µL by PCR under standard conditions: 1.5 mM MgCl2,
125 µM dNTP and 2.5 U Taq polymerase using spe-
cific primers at 10 µM concentration.
Cytoplasmatic beta actin: 375 bp; 32 cycles
(94oC, 1 min / 55oC, 30 sec / 72oC, 30 sec) S: 5’-
CGTGACATTAAGGAGAAGCTG -3’; AS: 3’-
CTCAGGAGGAGCAATGATCTTGA -5’
Beta-2 microglobulin: 225 bp; 25 cycles (94oC,
1 min / 55oC, 30 sec / 72oC, 30 sec) S: 5’-
GAATTCACACCCACCGAGAC -3’; AS: 3’-
CCGGATCTGGAGTAAACTGG -5’
Cytochrome oxidase subunit I: 238 bp; 32
cycles (94oC, 1 min / 55oC, 30 sec / 72oC, 30 sec) S:
5’- TCGCATCAAAACGAGAAGTG -3’; AS: 5’-
GGGTTCGAATCCTTCCTTTC -3’
Vascular endothelial growth factor: 370 / 450
/ 500 / 600 bp; 35 cycles (94oC, 1 min / 58oC, 30 sec /
72oC, 30 sec) S: 5’- TGCACCCACGACAGAAGGC
-3’; AS: 3’- TCACCCCCTTGGCTTGTCACAT -5’
The amplified PCR products were separated
on 2% agarose gel containing 0.1 µg/mL ethidium bro-
mide. The visualized bands were analyzed semi-quan-
titatively using image-scanning densitometry (Kodak
EDAS 120).
RESULTS
Using the genetic cDNA screening
microarray method with membranes of 1176 gene we
observed that 76 presented a differential expression
of at least two times between the two groups, of which
50 genes with lower expression in the group of cas-
trated rats (I) and 26 in the group of non-castrated
rats (II). These genes are involved in several steps of
biomolecular and cellular processes (Tables-1 and 2).
The analyses of the images of agarose gel
electrophoresis of the RT-PCR products confirm the
data of differential gene expression in the two groups
observed with microarrays for beta-2 microglobulin
(β2M) and cytochrome c oxidase subunit I (COX I)
genes (Figure-1). The two genes were less expressed
in group I, the differences (DIF) between the groups
being 1.54 and 1.65, respectively.
The difference in expression (DIF) in the ar-
rays for the cytoplasmic beta actin housekeeping gene
(ACTB), used in RT-PCR, was 0.12, proving mem-
brane normalization.
We performed RT-PCR for amplification of
the vascular endothelial growth factor (VEGF) in both
groups and observed a lower expression of this gene
in group I rats (Figure-1).
COMMENTS
We believe that depth in study of genes,
biomolecular and cellular control mechanisms, as well
as interaction of endogenous and exogenous factors
with the genetic material of the cells would help our
understanding of the pathophysiological processes that
give rise to urogynecological diseases.
After screening 1176 genes with the help of
the cDNA microarray technology, we identified 76
differential expression genes between the groups. In
practice, it is not easy to distinguish the real differ-
ences in gene expression where there is a difference
due to artifacts of technical variations. We consid-
ered differentially expressed genes with a difference
in expression of at least two times between the groups,
a value recommended by the statistical literature on
array analysis, whose estimated error rate is 1% (20-
22).
Gene screening allowed us to prove the influ-
ence of thirty-day castration of rats on gene expres-
sion in the organs of the lower urinary tract. The iden-
tified genes are involved in different cell activities:
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regulation of the cell cycle, turnover and translation
of proteins and extracellular signaling, growth and cell
metabolism, neurotransmission.
Among the genes identified as differentially
expressed, we chose two genes, COX I and β2M, to
be confirmed by RT-PCR, in view of the complexity
of the used methodology.
We also analyze the expression of VEGF gene
by RT-PCR, faced to the importance of the vascular-
ization in the maintenance of urinary continence (2)
and the demonstration of serum VEGF level decrease
after menopause with the loss of ovarian function (23).
The VEGF gene is involved in the process of
tissular angiogenesis (24) and thus, as with other
growth factors, has its expression modulated by sexual
steroids (25).
The VEGF protein is a polypeptide with a spe-
cific effect on cells of the vascular endothelium and
vascular permeability and is the most potent mitogenic
and proliferation factor of endothelial cells (26).
Experiments demonstrated serum levels of
VEGF decreased after menopause with loss of ova-
rian function (23) and some authors described quanti-
tative variations in VEGF according to the hormonal
status. Andrade et al. (17) observed a significant de-
crease in levels of messenger RNA for VEGF in the
endometrium of castrated adult rats when compared
to the group of rats with estrogen replacement.
Table 1 – Genes lower expressed in Group II.
GenBank                                                                        Genes DIF
D84550 LEPTIN RECEPTOR PRECURSOR (LEPR); OB RECEPTOR (OBR); FA -6.41
Z27118 HEAT SHOCK 70-KDA PROTEIN (HSP70) -5.17
X54793 HEAT SHOCK 60-KDA PROTEIN (HSP60); 60-KDA CHAPERONIN (CPN60); GROEL HOMOLOG -3.73
M36317 THYROLIBERIN PRECURSOR; THYROTROPIN-RELEASING HORMONE PRECURSOR (TRH) -3.44
M31838 SUBSTANCE K RECEPTOR (SKR); NEUROKININ A RECEPTOR; NK-2 RECEPTOR -2.95
X13412 FLK TYROSINE-PROTEIN KINASE; FPS/FES-RELATED -2.82
U67958 URATE TRANSPORTER/CHANNEL -2.42
U15098 GLUT AND GLUT-R GLUTAMATE TRANSPORTER -2.19
Z14119 PLATELET-DERIVED GROWTH FACTOR RECEPTOR. ALPHA -1.89
M86240 FRUCTOSE-16-BISPHOSPHATASE, LIVER -1.86
J03572; M1 ALKALINE PHOSPHATASE -1.82
L08493 GAMMA-AMINOBUTYRIC ACID RECEPTOR ALPHA 4 SUBUNIT PRECURSOR (GABA(A)
        RECEPTOR -1.52
M59980 VOLTAGE-GATED K+ CHANNEL PROTEIN; RK5; POTASSIUM CHANNEL PROTEIN -1.48
M58370 COLIPASE PRECURSOR (CLPS) -1.45
U96920 + U INOSITOL POLYPHOSPHATE 4-PHOSPHATASE TYPE II ALPHA +BETA -1.34
X16054 BILE-SALT-ACTIVATED LIPASE PRECURSOR (BAL); BILE-SALT-STIMULATED LIPASE (BSSL) -1.27
U59809 MANNOSE-6-PHOSPHATE/INSULIN-LIKE GROWTH FACTOR II RECEPTOR (M6P/IGFR2) -1.21
J02998 RAS-RELATED PROTEIN RAB1A -1.20
D32249 NEURODEGENERATION ASSOCIATED PROTEIN 1; DOWNREGULATED BY AXOTOMY -1.20
M63837 PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR (PDGFRA) -1.15
J05189 NEUROMEDIN K RECEPTOR (NKR); NEUROKININ B RECEPTOR; NK-3 RECEPTOR (NK-3R) -1.12
U10097 SODIUM/CHLORIDE COTRANSPORTER, THIAZIDE SENSITIVE -1.06
L15453 VOLTAGE-ACTIVATED CALCIUM CHANNEL ALPHA-1 SUBUNIT (RBE-II) -1.04
M31178 CALBINDIN D28; AVIAN- TYPE VITAMIN D-DEPENDENT CALCIUM-BINDING PROTEIN (CABP) -1.02
M32801 + J 3-KETOACYL-COA THIOLASE A + 3-KETOACYL-COA THIOLASE B -1.02
M30705 SEROTONIN 5HT2 RECEPTOR -1.00
DIF = difference in expression.
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GenBank                                                                         Genes DIF
J05029 LONG CHAIN-SPECIFIC ACYL-COA DEHYDROGENASE PRECURSOR 1.04
L22022 NEUROTRANSMITTER TRANSPORTER, SODIUM DEPENDENT 1.06
M64092 PKI-BETA; CAMP-DEPENDENT PROTEIN KINASE INHIBITOR (TESTIS FORM) 1.08
D30041 RAC-BETA SERINE/THREONINE KINASE (RAC-PK-BETA); AKT2 1.11
M15427 C-RAF PROTO-ONCOGENE; RAF-1 1.12
U02983 SECRETOGRANIN 3 (SG3) 1.12
M27716 DOPA DECARBOXYLASE ; AROMATIC-L-AMINO-ACID DECARBOXYLASE 1.12
M85301 SODIUM/HYDROGEN EXCHANGE PROTEIN 4 1.13
L33869; J0 CERULOPLASMIN PRECURSOR (CP); FERROXIDASE 1.14
L07925 RALGDSB; GTP/GDP DISSOCIATION STIMULATOR FOR A RAS-RELATED GTPASE 1.17
U27767 RGS4; REGULATOR OF G-PROTEIN SIGNALING 4 (RGP4). 1.17
U35174 SODIUM CHANNEL SHRSPHD, BETA SUBUNIT, EPITHELIAL 1.17
X59601 PLECTIN 1.18
M91466 ADENOSINE A2B RECEPTOR (ADORA2B) 1.18
M17526 GUANINE NUCLEOTIDE-BINDING PROTEIN G(O) ALPHA SUBUNIT (GNAO; GNA0) 1.18
M22413 CARBONIC ANHYDRASE III (CA3); CARBONATE DEHYDRATASE III 1.24
U62897 CARBOXYPEPTIDASE D PRECURSOR (CPD) 1.26
M95780 G PROTEIN, GAMMA 5 SUBUNIT 1.27
M37394 EPIDERMAL GROWTH FACTOR RECEPTOR (EGF RECEPTOR; EGFR) 1.28
S83440 14-3-3 PROTEIN BETA/ALPHA; PREPRONERVE GROWTH FACTOR RNH-1 1.34
X59949 NITRIC OXIDE SYNTHASE 1 1.37
X55446 CYTOCHROME P-450 2C23, ARACHIDONIC ACID EPOXYGENASE 1.43
L24907+L2 CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1 1.44
L42810 C  CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE; PHOSPHORYLASE B KINASE
     KINASE 1.48
M32167 GLIOMA-DERIVED VASCULAR ENDOTHELIAL CELL GROWTH FACTOR 1.50
Z14117 PLATELET-DERIVED GROWTH FACTOR B-CHAIN (PDGFB ); C-SIS 1.54
X16956 + U MICROGLOBULIN; BETA-2-MICROGLOBULIN + PROSTAGLANDIN RECEPTOR F2A 1.54
J02852 CYTOCHROME P450 2A3 (CYP2A3); COUMARIN 7-HYDROXYLASE 1.59
M33962 PROTEIN TYROSINE PHOSPHATASE PTPASE 1.61
X70062 ATPASE, SODIUM/POTASSIUM, GAMMA SUBUNIT 1.62
S79304 CYTOCHROME OXIDASE, SUBUNIT I, SERTOLI CELLS 1.65
M34728 NONSPECIFIC LIPID-TRANSFER PROTEIN PRECURSOR; STEROL CARRIER PROTEIN 2 AND X 1.65
X63675 PIM1 PROTO-ONCOGENE 1.66
M18331 PROTEIN KINASE C EPSILON TYPE (PKC-EPSILON) 1.71
L38247 SYNAPTOTAGMIN IV (SYT4) 1.72
L29090 GUANINE NUCLEOTIDE-BINDING PROTEIN G(I)/G(S)/G(T) BETA SUBUNIT 3 (GNB3) 1.75
D38260 PROTEIN PHOSPHATASE 2A 55-KDA REGULATORY SUBUNIT BETA (PP2ABRB; PPP2R2B) 1.79
L35771 G PROTEIN-ACTIVATED INWARD RECTIFIER POTASSIUM CHANNEL 4 (GIRK4) 1.87
L38615 GLUTATHIONE SYNTHETASE (GSH SYNTHETASE; GSH-S; GSS); GLUTATHIONE SYNTHASE 1.91
AB000507 AQUAPORIN 7 (AQP7) 2.01
U90556 PHOSPHATIDATE PHOSPHOHYDROLASE TYPE 2 2.06
D83598 SULFONYLUREA RECEPTOR 2.12
U48246 PROTEIN KINASE C-BINDING PROTEIN NEL HOMOLOG 2 2.16
X62146; S3 RIBOSOMAL PROTEIN L11 2.21
X13817 CALMODULIN (CALM; CAM) 2.23
Z25868 BONE MORPHOGENETIC PROTEIN 2 2.27
L08227 NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN ALPHA 6 SUBUNIT PRECURSOR 2.44
U10096 SODIUM-POTASSIUM-CHLORIDE COTRANSPORTER, BUMETANIDE-SENSITIVE 2.79
D10831 L-SELECTIN PRECURSOR;LYMPHNODE HOMING RECEPTOR;LEUKOCYTE ADHESION
     MOLECULE1 2.86
Table 2 – Genes lower expressed in Group I.
DIF = difference in expression.
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Agrawal et al. (27), using Doppler velocimetry
in postmenopausal women, showed an increase in
pulsatility indexes in carotid and uterine arteries, re-
flecting a higher vascular resistance in this phase, a
process that was reversed after estrogen therapy with
a subsequent increase in serum VEGF concentrations.
Zucchi et al. (28) observed protein expression
of VEGF gene in the bladder, vesical-urethral junction
and urethra of castrated and non-castrated rats had
been verified significantly decrease of VEGF in cas-
trated rat bladders compared to another group. There
was also protein decrease in vesical-urethral junction
even though not as accentuated as in the bladder.
Our observation of lower VEGF gene expres-
sion in urinary tract in castrated rats with ovarian hor-
mones deficient could be associated to local blood
vessel formation decrease. It would possibly contrib-
ute to the appearance of undesirable urinary symp-
toms such as irritating bladder and urethral symptoms,
urinary incontinence and urinary infection, too com-
mon in postmenopausal women, by decreasing local
circulation, oxygen offer and immunological defense.
COX I is a gene of mitochondrial DNA which
encodes for cytochrome c oxidase subunit I that be-
longs to the respiratory complex IV and involved in
the process of oxidative phosphorylation of cell (29).
It was suggested postmenopausal would have
reduced capacity to perform prolonged intensive ex-
ercises after evidence of decrease of cytochrome
oxidase activity by 40%, consequently, decrease of
oxidase phosphorilation to obtain energy in muscles
of ovariectomized rats exposed into stimulation (30).
Abelenda & Puerta (31) suggested ovarian
sex hormones regulate oxidative capacity by studying
ovariectomized animals. They concluded estrogen
deprivation analyzed with ovariectomized rats exposed
Figure 1 – Validation of array data by semi-quantitative RT-PCR. Beta Actin was housekeeping gene.
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to low temperature increases cytochrome oxidase
activity in whole body thermogenic tissues, such as
adipose tissue, soleus muscle, hearth, striated muscles,
liver and kidneys. In the same study, authors did not
observe alteration in enzyme complex activity in uterus
after ovariectomy.
Tong-Long Lin et al. (32) studied the effect
of age on mitochondrial enzyme activity in rat blad-
ders while evaluating the following enzyme activities:
citrate synthetase, malate dehydrogenase, NADH-cy-
tochrome c reductase, succinate-cytochrome c reduc-
tase and cytochrome c oxidase, in addition to phos-
phocreatine and ATP concentrations in bladders of 24-
month-old female rats. The authors observed signifi-
cantly lower phosphocreatine and ATP levels and sig-
nificantly lower enzyme activities, mainly of citrate
synthetase, in bladders of old rats. They concluded
that age reduced the activity of mitochondrial enzymes
of rat bladders, resulting in less ability of energy pro-
duction that could explain some micturition disorders
frequent in elderly patients.
Adequate energy supply is a prerequisite for
good vesical functioning, muscle contraction and vesi-
cal emptying. Cell energy, in the form of ATP origi-
nating from mitochondrial oxidative phosphorylation
is the immediate energy used for contraction of de-
trusor muscles and other cell activities (32). Levin et
al. (33) demonstrated that interruption of the oxida-
tive metabolism abolished the plateau component of
detrusor muscle contraction, resulting in decrease in
the ability of vesical empting.
Our result demonstrated reduced expression
of Cytochrome c oxidase subunit I gene in castrated
rats. Thus, decrease in expression of genes of cell
respiration may be one of the mechanisms by which
ovarian sex hormones deficiency promote alteration
in urinary tract metabolism and alterations in energy
acquisition by cells needed for physiological activities
such detrusor contraction.
The â2M gene encodes for the protein of the
same designation that is a component of HLA anti-
gens (histocompatibility antigens), being essential for
their expression. It is structurally similar to the amino
acid sequences of immunoglobulins and is implied in
immunologic functions (34,35).
β2M function has not been completely clari-
fied yet. However, it is postulated that β2M would be
a link between antibodies or IgG and histocompatibil-
ity antigens. Therefore, it would have the function of
cellular recognition of antigens and interaction of the
cellular and humoral immune systems, by interaction
between T and B lymphpocytes (35).
Several evidences support the hypotheses of
regulation of immunologic functions by gonadal ste-
roids: different behavior of immune system between
men and women, alterations in immune response af-
ter gonadectomy, estrogen replacement and in
women during pregnancy. Even so, hormone steroids
receptors are identified in immune system organs
(36).
Most scientific evidence demonstrates that
particularly estrogens act as stimulators of the humoral
immune response and as inhibitors of the cellular im-
mune response (37).
Some authors studied different system im-
mune compounds under ovarian hormones deficit.
Kamada et al. (38) on studying T cell function in meno-
pausal women observed lower quantity of Th1
cytokines, inducers of the cellular immune response,
and imbalance in the relationship between the latter
and Th2 cytokines, inducers of the humoral immune
response.
Giglio et al. (39) detected reduced number of
T CD4+ and B lymphocytes in postmenopausal pe-
riod compared to young women. The same result for
T lymphocytes weren’t observed by Yang et al. (40),
that also related NK cells toxicity were decreased in
postmenopause, situation reverted by estrogen therapy.
Flory et al. (41) analyzed some parameters
of immunological response as toxicity number and
mitogenic response of NK cells in women treated with
GnRH agonist and estrogen replacement thereafter.
Temporary suppression of ovarian function in addi-
tion to estrogen therapy did not alter those param-
eters. Authors postulated immunological suppression
findings are temporarily stable and possibly related to
age, life style, associated diseases.
In our study 30 days period of castration were
enough to reduce β2M gene expression. Maybe, sys-
tem immune alterations after menopause observed by
some authors can be at least partially mediated by
β2M expression. It is possible that decreased expres-
sion of β2M in lower urinary tract is associated to
increase of urinary infection.
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However, the real function of β2M protein in
immune responses, its association with infectious pro-
cesses and the participation of the immune system
specifically in the genesis of urinary infections in the
postmenopausal period have to be better elucidated.
In our experience, cDNA microarray technol-
ogy is a good screening method of genes of the lower
urinary tract and is also efficient in the studies on mo-
lecular alterations induced by estrogen deficiency.
The high prevalence of urinary disorders in
postmenopausal women justifies all efforts for their
better understanding, treatment and prophylaxis, in the
insisting attempt for a better quality of life.
This study deals with gene screening, and in-
numerable genes and protein still have to be evalu-
ated and confirmed. Thus, on the basis of knowledge
on genomics and pharmacogenomics, perhaps in the
future we may identify new targets for drug action
and make available therapeutic options for urinary dis-
orders.
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EDITORIAL COMMENT
This is an experimental study in rats, which
has Institutional Review Board approval, examining
the influence of estrogens deprivation on genes
expression in the lower urinary tract. They identified
76 differential expression genes between ovarian
hormone deprivation group and non-deprivation group
using the genetic cDNA screening microarray
methodology. So they analyze the difference of the
expression of the same gene in the two groups and
validation was confirmed for three lower expressed
genes, i.e., vascular Endothelial growth factor
(VEGF), Beta-2 Microglobulin (B2M) and
Cytochrome c Oxidase subunit I (COX I). These
genes are related to angiogenesis, immune responses
and cellular metabolism respectively.
After all, they try to correlate biomolecular
findings with urinary disorders usually seen on
postmenopausal women by reviewing the literature.
The authors hypothesized that lack of gene expression
could be responsible for urinary disorders in
postmenopausal women.
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